← boothcheck All Stocks

CNS

COHEN & STEERS, INC.

At today's price, COHEN & STEERS, INC. (CNS) is priced for +19.3% earnings growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.

Live priced in
+19.3% earnings growth
Priced In
elevated

Key Takeaways

Cohen & Steers is a specialist asset manager whose value is a multiple on a fee stream, not on book value. With assets under management at $93.1 billion, an effective fee rate near 67 basis points on its open-end funds, and a trailing return on equity around 28% on a tiny equity base, the economics are capital-light and high-margin. The recent results are good: first-quarter 2026 revenue of $145.6 million, diluted EPS of $0.82, a 34.4% operating margin, and $497 million of net inflows that mark

View Full Report →

Is CNS overvalued? See what's priced in →

Institutional ownership

282 institutional managers reported holding CNS in 13F filings for the quarter ended 2026-03-31. Together they hold about 52% of the company; the top 10 hold 31%. 45 opened new positions that quarter. Held by BlackRock, Vanguard Group, Dimensional Fund Advisors, among others. On the short side, 1.2M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (4.9 days of typical volume to cover).

Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.

Capital returns

CNS's share count grew 6.5% over the past five years even with $116.05M spent on repurchases. It pays a dividend, and has paid one every year in our records (16 and counting), raised 3 years straight; the current rate is $2.48 a share annually. Cash returned over the past three years: $336.87M in dividends and $67.35M in repurchases.

Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.

Insider activity

Open-market insider buys at CNS over the trailing three years: 2025: 24 buys totaling $17.18M. 20 officers and directors are on file.

Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.

Earnings reactions

CNS's recent reports: the day-one move, then what the following quarter actually did.

reportday onenext quarter
2023-08-05+0.7%-7.5%
2023-11-04-6.1%+21.9%
2024-02-24+2.3%-2.0%
2024-05-04+2.1%+2.2%

Day-one is the close-to-close move around the filing. Nothing here is investment advice.

Recent filings

CNS's latest 8-K filings: 2026-07-16 (items 2.02, 9.01); 2026-05-21 (items 5.02, 7.01, 9.01); 2026-05-04 (items 5.07); 2026-04-16 (items 2.02, 9.01); 2026-01-22 (items 2.02, 9.01).

Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.

Compare CNS

Browse all stock reportsOpen the screener

Last analyzed: June 27, 2026

For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.